Nuclear Innovation to Advance New Cancer Treatments

TerraPower Isotopes® (TPI®) is transforming the fight against cancer by advancing the next generation of isotopes. The TPI team is utilizing proven methods to extract research grade1, actinium-225, free of the isotopic impurities of actinium, which may be applied to new medical applications that potentially target and treat cancer. TPI is increasing the scarce global supply of actinium-225, an isotopic starting material, to support pharmaceutical companies’ cancer research and development efforts.

Producing Actinium-225 in Support of Targeted Alpha Therapy Research for Cancer Patients

Since 2018, TerraPower Isotopes has been working to increase the supply of actinium-225. Actinium-225 is an alpha-emitting radionuclide that may have application in the area of oncology targeted alpha therapy research and development. The isotope can be attached to a molecule, which can then selectively target and deliver the actinium-225 to the cancer site. The actinium-225 labeled drug products, once developed and approved, can destroy the cancerous tissue with minimum damage to nearby healthy cells. The TPI team of experts is bringing the next generation of isotopes to market using a natural decay method to produce actinium-225 free of isotopic impurities. This method increases the efficiency and automation of the process, which enables TPI to produce a significant, consistent supply of the isotope to the market.

Partnering to Bring the Future of Precision Medicine to Market

TerraPower Isotopes is actively working to provide research grade actinium-225 to pharmaceutical companies for potential drug development through partnerships with private industry and government. The program’s innovative technologies will support the potential development and availability of a diverse suite of cancer treatments. The TPI team is producing actinium-225 at commercial scale, providing sustained access to highly pure actinium-225 to the global pharmaceutical community through weekly production runs. As a result, TerraPower Isotopes’ Actinium, after further manufacturing, is now used in multiple drug developer’s radiopharmaceuticals in human clinical trials across the globe. It is the first company to provide actinium-225 at this scale and is transforming how the pharmaceutical industry approaches cancer treatment with targeted alpha therapies. TerraPower Isotopes works with the U.S. Department of Energy’s Oak Ridge Office of Environmental Management and Isotek Systems, LLC to increase the supply of actinium-225 by harvesting the isotope from thorium-229 decay, which is derived from legacy U.S. nuclear material, uranium-233, through an innovative public-private partnership. TerraPower Isotopes also collaborates with a variety of industry partners to expand the availability of this isotope, including Cardinal Health, which routinely produces and distributes TerraPower’s actinium-225 product for use in drug trials involving targeted alpha therapy. Through these partnerships, the TPI team expects to increase the supply of actinium-225 exponentially to advance the next generation of cancer treatment.

Learn More about Isotopes

Our fact sheet offers a deeper look at TPI and the mission. Download the Fact Sheet

Learn more at www.terrapower.com.

TerraPower Isotopes, LLC is a subsidiary of TerraPower, LLC.